

This designation will become effective on July 22, 2007, unless Congress provides otherwise prior to the effective date. After this effective date, HHS will publish a notice in the **Federal Register** reporting the addition of this class to the SEC or the result of any provision by Congress regarding the decision by HHS to add the class to the SEC.

**FOR FURTHER INFORMATION CONTACT:**

Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C-46, Cincinnati, OH 45226, Telephone 513-533-6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to [OCAS@CDC.GOV](mailto:OCAS@CDC.GOV).

**John Howard**

Director, National Institute for Occupational Safety and Health.

[FR Doc. 07-3686 Filed 7-27-07; 8:45 am]

**BILLING CODE 4160-17-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Agency for Healthcare Research and Quality Notice of Meeting**

In accordance with section 10(d) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2), announcement is made of a Health Care Policy and Research Special Emphasis Panel (SEP) meeting.

A Special Emphasis Panel is a group of experts in fields related to health care research who are invited by the Agency for Healthcare Research and Quality (AHRQ), and agree to be available, to conduct on an as needed basis, scientific reviews of applications for AHRQ support. Individual members of the Panel do not attend regularly-scheduled meetings and do not serve for fixed terms or a long period of time. Rather, they are asked to participate in particular review meetings which require their type of expertise.

Substantial segments of the upcoming SEP meeting listed below will be closed to the public in accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 552b (c)(6). Grant applications for the Announcement of Availability of Funds for Grants regarding Minority Research Infrastructure Support Program (M-RISP) applications are to be reviewed and discussed at this meeting. These discussions are likely to reveal personal information concerning individuals associated with the applications. This

information is exempt from mandatory disclosure under the above-cited statutes.

**SEP Meeting on:** Minority Research Infrastructure Support Program (M-RISP).

**Date:** August 23, 2007 (Open on August 23 from 2 p.m to 2:15 p.m. and closed for the remainder of the meeting).

**Place:** John M. Eisenberg Building, AHRQ Conference Center, 540 Gaither Road, Rockville, Maryland 20850.

**Contact Person:** Anyone wishing to obtain a roster of members, agenda or minutes of the non-confidential portions of this meeting should contact Mrs. Bonnie Campbell, Committee Management Officer, Office of Extramural Research, Education and Priority Populations, AHRQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850, Telephone (301) 427-1554.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: July 23, 2007.

**Carolyn M. Clancy,**

Director.

[FR Doc. 07-3679 Filed 7-27-07; 8:45 am]

**BILLING CODE 4160-90-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Medicare & Medicaid Services**

**Privacy Act of 1974; Retraction of a New System of Records**

**AGENCY:** Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS).

**ACTION:** Notice of retraction of a new system of records.

**SUMMARY:** The Centers for Medicare & Medicaid Services CMS inadvertently published a new system of records titled "Post Acute Care Payment Reform/Continuity of Assessment Report and Evaluation Demonstration and Evaluation (PAC-CARE)" System No. 09-70-0569 in the **Federal Register** (FR) on Thursday, April 19, 2007 (72 FR 19711). CMS is withdrawing the notice due to comments received that a routine use disclosure provision necessary to carry out essential parts of the demonstration project was inadvertently omitted. The notice of a new system of records will be republished at a later date with the routine use included.

**FOR FURTHER INFORMATION CONTACT:** Inquiries may be directed to: CMS Privacy Officer, Division of Privacy Compliance, Enterprise Architecture and Strategy Group, Office of

Information Services, CMS, Room N2-04-27, 7500 Security Boulevard, Baltimore, Maryland 21244-1850. He can also be reached at 410-786-5357 or by e-mail at [walter.stone@cms.hhs.gov](mailto:walter.stone@cms.hhs.gov).

Dated: July 18, 2007.

**William Saunders,**

Acting Deputy Director, Office of Information Services, Centers for Medicare & Medicaid Services.

[FR Doc. E7-14631 Filed 7-27-07; 8:45 am]

**BILLING CODE 4120-03-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Assuring Radiation Protection; Cooperative Agreement; Request for Applications: RFA-FDA-CDRH-07-004; Catalog of Federal Domestic Assistance Number: 93.103**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**I. Funding Opportunity Description**

The Food and Drug Administration (FDA) is announcing its intention to receive and consider applications for the award of a cooperative agreement in fiscal year 2007 (FY07) to provide support in furtherance of FDA's responsibilities, under section 532 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ii), to establish and carry out a comprehensive radiation control program. An estimated amount of support in FY07 will be for up to \$400,000, with an additional 5 years of support, subject to the condition that in addition to FDA funds, augmenting funds are transferred to FDA from other Federal agencies to fully support this program. Funds may not be used to fund or conduct international activities or initiatives. As the lead Federal agency, FDA intends to collect funds from all other contributing Federal agencies through Interagency Agreements and fund one award for up to \$400,000 in total costs (including both direct and indirect costs). After the first year, additional years of noncompetitive support are predicated upon acceptable performance during the preceding year and the availability of Federal funds.

The cooperative agreement will allow FDA to continue to work with the Nuclear Regulatory Commission and its predecessor organizations, the Environmental Protection Agency and the Federal Emergency Management Agency, to provide financial support for a forum established to foster the exchange of ideas and information